These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 2109678)

  • 21. A meta-analysis of trials on aldose reductase inhibitors in diabetic peripheral neuropathy. The Italian Study Group. The St. Vincent Declaration.
    Nicolucci A; Carinci F; Cavaliere D; Scorpiglione N; Belfiglio M; Labbrozzi D; Mari E; Benedetti MM; Tognoni G; Liberati A
    Diabet Med; 1996 Dec; 13(12):1017-26. PubMed ID: 8973882
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aldose reductase inhibitors and diabetic complications.
    Raskin P; Rosenstock J
    Am J Med; 1987 Aug; 83(2):298-306. PubMed ID: 3113248
    [No Abstract]   [Full Text] [Related]  

  • 23. [Role of aldose reductase inhibitors in the development of peripheral neuropathy in experimental diabetes].
    Kuchmerovskaia TM; Donchenko GV; Klimenko AP; Chichkovskaia GV; Pakirbaeva LV; Kozitskiĭ ZIa; Efimov AS
    Ukr Biokhim Zh (1978); 1997; 69(3):77-82. PubMed ID: 9505366
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A multicentre trial of the aldose-reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy.
    Boulton AJ; Levin S; Comstock J
    Diabetologia; 1990 Jul; 33(7):431-7. PubMed ID: 2119323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical experience with sorbinil--an aldose reductase inhibitor.
    Pitts NE; Vreeland F; Shaw GL; Peterson MJ; Mehta DJ; Collier J; Gundersen K
    Metabolism; 1986 Apr; 35(4 Suppl 1):96-100. PubMed ID: 3083213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aldose reductase inhibitors for the prevention and treatment of diabetic peripheral neuropathy.
    Airey M; Bennett C; Nicolucci A; Williams R
    Cochrane Database Syst Rev; 2000; 1996(2):CD002182. PubMed ID: 10796870
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical application of aldose reductase inhibitors--prevention and therapy of diabetic complications].
    Hotta N; Sakamoto N
    Nihon Rinsho; 1987 Dec; 45(12):3010-27. PubMed ID: 3128677
    [No Abstract]   [Full Text] [Related]  

  • 28. The role of aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy.
    Yue DK; Brooks B
    Med J Aust; 1993 Jul; 159(2):76-8. PubMed ID: 8336605
    [No Abstract]   [Full Text] [Related]  

  • 29. Prolonged aldose reductase inhibition in chronic peripheral diabetic neuropathy: effects on microangiopathy.
    Jennings PE; Nightingale S; Le Guen C; Lawson N; Williamson JR; Hoffman P; Barnett AH
    Diabet Med; 1990 Jan; 7(1):63-8. PubMed ID: 2137066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review.
    Schemmel KE; Padiyara RS; D'Souza JJ
    J Diabetes Complications; 2010; 24(5):354-60. PubMed ID: 19748287
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An aldose reductase inhibitor, TAT, reduces ADP-induced platelet hyperaggregation in streptozotocin-induced diabetic rats with neuropathy.
    Hara T; Nakamura J; Koh N; Sakakibara F; Hamada Y; Sasaki H; Naruse K; Nakashima E; Takeuchi N; Inukai S
    J Lab Clin Med; 1995 Dec; 126(6):541-7. PubMed ID: 7490513
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aldose reductase inhibition in diabetic neuropathy: clinical and neurophysiological studies of one year's treatment with sorbinil.
    O'Hare JP; Morgan MH; Alden P; Chissel S; O'Brien IA; Corrall RJ
    Diabet Med; 1988 Sep; 5(6):537-42. PubMed ID: 2974776
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy.
    Florkowski CM
    Med J Aust; 1993 Nov; 159(10):711-2. PubMed ID: 8110237
    [No Abstract]   [Full Text] [Related]  

  • 34. Diabetic complications in lens and nerve and their prevention by sulindac or sorbinil: two novel aldose reductase inhibitors.
    Jacobson M; Sharma YR; Cotlier E; Hollander JD
    Invest Ophthalmol Vis Sci; 1983 Oct; 24(10):1426-9. PubMed ID: 6413448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aldose reductase, still a compelling target for diabetic neuropathy.
    Oates PJ
    Curr Drug Targets; 2008 Jan; 9(1):14-36. PubMed ID: 18220710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of aldose reductase inhibitors on the progression of nerve fiber damage in diabetic neuropathy.
    Greene DA
    J Diabetes Complications; 1992; 6(1):35-8. PubMed ID: 1562756
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of diabetes-related retinal microangiopathy with aldose reductase inhibitors.
    Robison WG
    Adv Exp Med Biol; 1988; 246():365-72. PubMed ID: 3150650
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of cyclic adenosine 3',5'-monophosphate and polyol metabolism in diabetic neuropathy.
    Shindo H; Tawata M; Aida K; Onaya T
    J Clin Endocrinol Metab; 1992 Feb; 74(2):393-8. PubMed ID: 1370506
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Autonomic and peripheral nerve function in early diabetic neuropathy. Possible influence of a novel aldose reductase inhibitor on autonomic function.
    Sundkvist G; Lilja B; Rosén I; Agardh CD
    Acta Med Scand; 1987; 221(5):445-53. PubMed ID: 3111179
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of diabetic neuropathy with inhibitors of the aldose reductase enzyme.
    Green AJ; Jaspan JB
    J Diabet Complications; 1990; 4(4):138-44. PubMed ID: 2151223
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.